HCPLive Network
Conferences
Conditions
Specialties

Phase 3 Trial of Experimental Gout Drug Lesinurad to Begin

Phase 3 Trial of Experimental Gout Drug Lesinurad to BeginArdea Biosciences announced on Monday that it would soon begin the first of four planned Phase 3 clinical trials of its experimental gout drug lesinurad. The trial is expected to include around 2,000 gout patients at study sites around the world.
 
Lesinurad is an oral inhibitor of the URAT1 transporter in the kidney that regulates uric acid excretion. According to a press release from Ardea Biosciences, around 90% of gout patients are thought to excrete too little uric acid, and studies have found that defective renal transporters, which promote excretion of uric acid under normal circumstances, are genetically linked to gout.
 
Since currently available gout drugs such as the xanthine oxidase inhibitors allopurinol and febuxostat have a mechanism of action different from URAT1 inhibitors, the hope is that lesinurad will be able to be used in conjunction with these other drugs to help the many gout patients who are not adequately treated with existing therapies alone. In previous Phase 1 and 2 trials, lesinurad has been tested on over 700 patients as a single agent and in combination with allopurinol and febuxostat.

Further Reading
“We really have entered this new era of direct acting antivirals, and as of this fall, we’ve finally laid to rest interferon in the grave that we’ve all been wanting to put it in, for more than 2 decades,” said Jacqueline G. O’Leary, MD, MPH, during her presentation at the 2015 AGA Clinical Congress of Gastroenterology & Hepatology.
Current targets call for 150 minutes of weekly exercise -- or 30 minutes of physical activity at least five days a week -- to reduce the risk of chronic diseases such as diabetes and cardiovascular disease. Although these standards don't need to be abandoned, they shouldn't be the primary message about exercise for inactive people, experts argue in two separate analyses published Jan. 21 in The BMJ.
Handwritten prescriptions will soon be illegal in New York. The Medical Society of the State of New York (MSSNY) and 18 national and NY State medical organizations are trying to delay for a year the onset of a law that would require electonic prescriptions, ban prescription pads, and drastically restrict phoned-in prescriptions. The measure, due to take effect March 27, would require electronic prescriptions for all medications—not just for controlled substances but antibiotics, allergy medications or anything else that requires a prescription.
More Reading